Galectin Therapeutics EPS -$0.48 Beats by $0.01: Galectin Therapeutics reported GAAP EPS -$0.48 on Mar 31, 2026, beating consensus by $0.01 (Seeking Alpha); focus shifts to cash runway and trial milestones. 👈 Read full analysis #GalectinTherapeutics #EPS #Biotech #ClinicalTrials #Investing
0
0
0
0